IPOGrid
0002079109
IPO filing research

Veraxa Biotech Holding AG

Pharmaceutical Preparations · VRXA

follow-on trading filed Nasdaq F-1

Veraxa Biotech Holding AG IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: F-1 on 2026-07-31. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR
F-1 filed
Initial foreign registration statement
Initial public filing for a foreign issuer submitted to start the SEC review process.
Follows F-1 in the pre-IPO sequence.
2026-07-31 · 0001829126-26-008247
F-1 filed
Initial foreign registration statement
Initial public filing for a foreign issuer submitted to start the SEC review process.
Follows 20-F in the pre-IPO sequence.
2026-07-31 · 0001829126-26-008246
20-F supplemental
20-F
Pre-IPO filing captured from the SEC submission timeline.
Follows CERT in the pre-IPO sequence.
2026-06-16 · 0001829126-26-006546
CERT inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2026-06-10 · 0001354457-26-000557
8-A12B effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows 424B3 and registers the class of securities for exchange listing.
2026-06-09 · 0001829126-26-006236
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Class A and Class B · SPAC Units separated into Class A Ordinary Shares and Warrants · SPAC Warrants converted into PubCo Warrants · Use of proceeds Business combination and related transactions · Flags cayman_holding_company, dual_class
Veraxa Biotech Holding AG's current 424B3 filing highlights significant risks associated with its clinical development pipeline. The company emphasizes that its product candidates face high uncertainty in clinical trials, including potential discontinuation due to lack of efficacy, safety concerns, or resource prioritization. Key risks include delays in trial completion, adverse events, challenges in patient enrollment, and regulatory hurdles. The filing underscores that none of its current product candidates may achieve commercial success, with potential material adverse impacts on business and financial outcomes.
2026-02-19 · 0001829126-26-001490
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows F-4/A and marks the registration effective.
2026-02-17 · 9999999995-26-000595
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
Flags cayman_holding_company
2026-02-13 · 0001829126-26-001295
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
Flags cayman_holding_company, foreign_private_issuer
2026-02-03 · 0001829126-26-000902
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior 425 filing.
SPAC Class A Ordinary Share · Each SPAC Unit includes one Class A Ordinary Share and one-half of a Warrant · Warrants exercisable for Class A Ordinary Shares at $11.50 per share · Use of proceeds Proceeds to be used for general corporate purposes · Flags cayman_holding_company, units
2025-11-28 · 0001829126-25-009492
425 supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows F-4/A in the pre-IPO sequence.
2025-09-30 · 0001829126-25-007783
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4/A filing.
SPAC Class A Ordinary Share · Flags cayman_holding_company, foreign_private_issuer · Underwriters self-underwritten
2025-09-29 · 0001829126-25-007725
F-4/A amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
Updates the prior F-4 filing.
SPAC Class A Ordinary Share · Use of proceeds for the business combination and related transactions · Flags cayman_holding_company, units
2025-07-31 · 0001829126-25-005637
F-4 filed
F-4
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
SPAC Class A Ordinary Share · Flags cayman_holding_company
2025-07-31 · 0001829126-25-005620
Comparable Deals

16 comparable deals

Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 16 using nearest neighbors.
Showing top 8 by similarity.
+9.1%
Median day-1
56%
Above issue
-1.3%
Median week-1
-20.9%
Downside (p10)
Apnimed, Inc. APMD
2026-07-31 $192M Day 1: +43.6% Wk 1: +43.6%
same SICrecent IPO
Kardigan, Inc. KARD
2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%
same SICrecent IPO
Parabilis Medicines, Inc. PBLS
2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%
same SICrecent IPO
Seaport Therapeutics, Inc. SPTX
2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%
same SICrecent IPO
Avalyn Pharma Inc. AVLN
2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%
same SICrecent IPO
First Tracks Biotherapeutics, Inc. TRAX
2026-04-20 - Day 1: -9.3% Wk 1: -11.5%
same SICrecent IPO
Kailera Therapeutics, Inc. KLRA
2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%
same SICrecent IPO
Scribe Therapeutics, Inc. SCTX
2026-07-24 $129M Day 1: +44.3% Wk 1: +22.4%
same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.